$SAVA $KOD $NKTR
ANRO🚀🚀🚀👇
Phase 2 proof-of-concept trials remain on track: Topline data expected from ALTO-203 in MDD in the second quarter🔥 of 2025 followed by ALTO-101 in schizophrenia in the second half 🔥of 2025
– Late-stage programs advancing: Topline data expected from the Phase 2b trial of ALTO-300 in MDD in mid-2026 followed by the Phase 2b trial of ALTO-100 in bipolar depression in the second half of 2026 –
New data presented at recent scientific conferences support Alto’s biomarker-driven pipeline and patient stratification approach –
Strong cash position of approximately $161.3 million expected to fund planned operations into 2028!!! and through at least four upcoming clinical study readouts – Bullish
2
4